BioCentury
ARTICLE | Clinical News

Serlopitant: Phase II started

June 30, 2014 7:00 AM UTC

Velocity Pharmaceutical Development LLC (San Francisco, Calif.) and Tigercat began a double-blind, placebo-controlled, German Phase II trial to evaluate 5 mg oral VPD-737 once daily for 8 weeks in about 60 patients with prurigo nodularis. VPD-737 is also being evaluated in a U.S. Phase II trial to treat chronic pruritus. ...